Company Encyclopedia
View More
name
Aadi Biosciences
AADI.US
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc.
1.912 T
AADI.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking190/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-65.95%E
    • Profit Margin-246.06%E
    • Gross Margin-49.76%E
  • Growth ScoreC
    • Revenue YoY7.80%B
    • Net Profit YoY2.72%C
    • Total Assets YoY-38.64%E
    • Net Assets YoY-41.73%E
  • Cash ScoreC
    • Cash Flow Margin-40.64%D
    • OCF YoY7.80%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio19.64%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals

    Whitehawk Therapeutics Inc :WHITEHAWK THERAPEUTICS COMPLETES STRATEGIC TRANSFORMATION WITH SUCCESSFUL CLOSING OF SALE OF AADI SUBSIDIARY TO KAKEN PHARMACEUTICALS

    Reuters·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    Reuters·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%

    Aadi takes flight with new moniker: Whitehawk Therapeutics

    Aadi Bioscience has rebranded as Whitehawk Therapeutics following a shift to preclinical biotech. The company will trade under the new ticker "WHWK" on Nasdaq. This change reflects its focus on antibody drug conjugates (ADCs) for cancer treatment, having licensed three ADCs from WuXi Biologics and Hangzhou DAC. The company plans to fund operations through 2028 after selling its Fyarro business to Kaken Pharmaceutical. CEO Dave Lennon emphasized the strategy to tackle challenging cancers with innovative technologies.

    Fiercepharma·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    Fiercepharma·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%

    08:00 ET Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

    Aadi Bioscience, Inc. (Nasdaq: AADI) will host a webcast on March 19, 2025, to discuss its fourth quarter and full-year 2024 financial results and provide corporate updates. The results will be accessible on the company's website under the "Investors & News" section. Aadi focuses on precision oncology, aiming to enhance therapies for challenging cancers.

    prnewswire·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    prnewswire·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%

    Aadi Bioscience IncQ) expected to post a loss of 22 cents a share - Earnings Preview

    Aadi Bioscience IncQ) is expected to report a loss of 22 cents per share and a 17.8% increase in quarterly revenue to $7.45 million for the period ending December 31, 2024. The average analyst rating is "hold" with a median 12-month price target of $3.00, above its last closing price of $2.10. The mean earnings estimate has remained unchanged over the last three months, with no strong buy or sell recommendations.

    Reuters·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    Reuters·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%

    Insider Selling: Aadi Bioscience, Inc. (NASDAQ:AADI) CEO Sells 5,690 Shares of Stock

    Aadi Bioscience, Inc. CEO David James Lennon sold 5,690 shares of stock at an average price of $2.35, totaling $13,371.50. Post-sale, he holds 33,429 shares valued at approximately $78,558.15, reflecting a 14.55% decrease in ownership. The transaction was filed with the SEC. Aadi's stock traded down to $2.30, with a market cap of $56.80 million. Institutional investors own 52.08% of the company, which focuses on precision therapies for genetically defined cancers.

    Market Beat·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    Market Beat·
    US
    AADI
    0.00%
    US
    WHWK
    -5.86%
    © 2025 Longbridge｜Disclaimer